Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rolofylline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 known ✓ | P30542 | 11/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 8/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 5/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 1.00 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 1.00 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.79 |
| ▸ | MAPT | P10636 | 1/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14051422 | 0.95 | ADORA1 (0.91) | ADORA1ADORA2AADORA2BADORA3SLC6A3 | |
| Rolofylline SCHEMBL13414155 | 0.94 | ADORA1 (0.88) | ADORA1ADORA2AADORA2BADORA3SLC6A3 | |
| SCHEMBL7270718 | 0.93 | ADORA1 (1.00) | ADORA1ADORA2AADORA2BADORA3SLC6A3 | |
| SCHEMBL8707422 | 0.93 | ADORA1 (0.86) | ADORA1ADORA2AADORA2BADORA3SLC6A3 | |
| SCHEMBL8705557 | 0.93 | ADORA1 (0.92) | ADORA1ADORA2AADORA2BADORA3SLC6A3 | |
| Rolofylline SCHEMBL13414105 | 0.92 | ADORA1 (0.86) | ADORA1ADORA2AADORA2BADORA3SLC6A3 | |
| SCHEMBL8707145 | 0.92 | ADORA1 (0.84) | ADORA1ADORA2AADORA2BADORA3SLC6A3 | |
| SCHEMBL8709754 | 0.91 | ADORA1 (0.83) | ADORA1ADORA2AADORA2BADORA3SLC6A3 | |
| SCHEMBL8705276 | 0.91 | ADORA1 (0.82) | ADORA1ADORA2AADORA2BADORA3SLC6A3 | |
| SCHEMBL8704417 | 0.91 | ADORA1 (0.82) | ADORA1ADORA2AADORA2BADORA3SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 267 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4648778-A1 | METHOD FOR TREATING NETOSIS-MEDIATED DISEASES | National Health Research Institutes (TW) | 2025-11-19 | — | — | EP | claimed |
| WO-2024151651-A1 | METHOD FOR TREATING NETOSIS-MEDIATED DISEASES | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2024-07-18 | — | — | WO | claimed |
| US-20210393857-A1 | SMALL MOLECULE DRUGS AND METHODS TO ACCELERATE OSSEOINTEGRATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-12-23 | — | — | US | claimed |
| EP-3876871-A1 | SMALL MOLECULE DRUGS AND METHODS TO ACCELERATE OSSEOINTEGRATION | The Regents of the University of California (US) | 2021-09-15 | — | — | EP | claimed |
| US-10024795-B2 | Method for monitoring vesicles using a membrane-permeable marker that is converted into a membrane-nonpermeable marker | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2018-07-17 | — | — | US | claimed |
| EP-2708897-B1 | Compositions and methods for detecting and analyzing vesicles | SAMSUNG ELECTRONICS CO LTD (KR) | 2017-09-06 | — | — | EP | claimed |
| CN-101977594-B | Suffer from the authentication method of patient and the treatment of this patient that mild cognitive impairment needs treatment | B.R.A.H.M.S GMBH (DE) | 2015-09-02 | — | — | CN | claimed |
| EP-2247287-B1 | Method for the identification of patients in need of therapy having minor cognitive disorders and the treatment of such patients | BRAHMS GMBH (DE) | 2015-08-12 | — | — | EP | claimed |
| US-20140099652-A1 | COMPOSITION FOR MONITORING VESICLE, KIT AND METHOD OF MONITORING VESICLE USING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2014-04-10 | — | — | US | claimed |
| US-20140080136-A1 | COMPOSITIONS, KITS, AND METHODS FOR DETECTING AND ANALYZING VESICLES | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2014-03-20 | — | — | US | claimed |
| US-6339072-B2 | Compositions and methods for preventing restenosis following revascularization procedures | DISCOVERY THERAPEUTICS INC. | 2002-01-15 | — | — | US | claimed |
| US-20010009907-A1 | Compositions and methods for preventing restenosis following revascularization procedures | DISCOVERY THERAPEUTICS, INC. | 2001-07-26 | — | — | US | claimed |
| US-6210687-B1 | EXHIBITS AN ADENOSINE A1 RECEPTOR ANTAGONIZING ACTIVITY, AND WHICH HAS ANTIHYPERTENSIVE ACTIVITY, DIURETIC ACTIVITY, KIDNEY-PROTECTING ACTIVITY, BRONCHIODILATARY ACTIVITY, BRAIN FUNCTION-IMPROVING ACTIVITY AND ANTIDEMENTIAL ACTIVITY. | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-04-03 | — | — | US | claimed |
| EP-0970696-A1 | Combination of loop diuretics with adenosine A1-receptor antagonists | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2000-01-12 | — | — | EP | claimed |
| EP-0958821-A1 | FAT EMULSION CONTAINING XANTHINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1999-11-24 | — | — | EP | claimed |
| WO-1998030900-A2 | SCREENING METHOD FOR COMPOUNDS ACTIVE IN TREATING MYOPIA AND HYPERMETROPIA | KLAUS TRIER APS (DK) | 1998-07-16 | — | — | WO | claimed |
| EP-0415456-B1 | Xanthine compounds | KYOWA HAKKO KOGYO KK (JP) | 1996-06-26 | — | — | EP | claimed |
| US-5504090-A | Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1996-04-02 | — | — | US | claimed |
| US-5290782-A | Bronchodilator agents, diuretics for renal protective agents | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1994-03-01 | — | — | US | claimed |
| EP-0415456-A2 | Xanthine compounds | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1991-03-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210393857-A1 | SMALL MOLECULE DRUGS AND METHODS TO ACCELERATE OSSEOINTEGRATION | PER2, NCOR2, NR4A2 | ADORA1 577/4885ADORA2A 254/4885ADORA2B 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.